Notably, patients who had documented psychotic and psychiatric disorders were more likely to be diagnosed with a demyelinating disease.
Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.
The relationship between microstructural damage in NAWM and clinical measures was less clear, suggesting another mechanism.
Researchers examined whether the cognitive reserve hypothesis could predict cognitive decline, gray matter volume changes, and white matter volume changes in MS patients.
High-fat diets may increase the risk of relapse in children with MS, while high-vegetable diets may be protective.
Six polymorphisms were found to be strongly associated with vitamin D levels in the patient population.
Axon diameter dynamics may serve as a novel biomarker for MS disease course.
Patients at the greatest risk of disability progression were older than 12 years, and had minimal exposure to DMTs.
Higher BMI and lipid levels were associated with greater risk of relapse and disability progression.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies